O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors Abstract #1337

Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.
Aim(s): To investigate the relationship between response to Aranoza-based therapy and MGMT expression.
Materials and methods: The MGMT expression was measured in 37 pts by immunohistochemistry using paraffin-embedded tissues. Tumors were scored as ‘‘intact’’ when the rate of positive cells was more than 10% with the intensity of staining 1+ and more. All consecutive pts with WD NETs treated with Аranoza alone or in combination with capecitabine, doxorubicin or temozolomide. Treatment efficacy was evaluated according to RECIST criteria v.1.0. The median PFS was calculated using Kaplan-Meier method.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Svetlana Polozkova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1275 Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova
#475 Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolamide in Patients with Digestive Neuroendocrine Tumors (NETs)
Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Olivia Hentic
Authors: Hentic O, Cros J, Rebours V, Zappa M, ...
#1245 Identification of Response Predictors to Temozolomide-Based Chemotherapy
Introduction: Capecitabine and temozolomide are active in the treatment of metastatic pNETs, with response rates ranging from 30% to 70%. Several small retrospective series have suggested that MGMT deficiency may predict response to temozolomide, however expression of MGMT has not been validated as a predictive biomarker. Cytotoxic chemotherapy is thought to be most active in aggressive tumors, however the ki-67 index has not been formally evaluated as a predictive factor. It is unclear whether chromosomal instability (which correlates with alternate lengthening of telomeres) predicts response.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Dr. Mauro Cives
#314 Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-Line Chemotherapy
Introduction: Patients with metastatic PDEC usually have a short survival. After first-line palliative chemotherapy, there are no established second-line treatments. Temozolomide has shown effect in other NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Staffan Welin
#1702 Comparative Retrospective Analysis of pNETs Treatment with Everolimus (E) and Sunitinib (S).
Introduction: Two targeted compounds are validated for treatment of pNETs – E and S.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Vera Gorbunova